首页> 美国卫生研究院文献>Balkan Journal of Medical Genetics : BJMG >TWIST1 Gene Expression as a Biomarker for Predicting Primary Doxorubicin Resistance in Breast Cancer
【2h】

TWIST1 Gene Expression as a Biomarker for Predicting Primary Doxorubicin Resistance in Breast Cancer

机译:TWIST1基因表达作为预测乳腺癌原发性阿霉素抗性的生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Doxorubicin is one of the most commonly used chemotherapeutic agents for adjuvant chemotherapy of breast cancer. In the studies focused on finding biomarkers to predict the response of the patients and tumors to the drugs used, the Twist transcription factor has been suggested as a candidate biomarker for predicting chemo-resistance of breast tumors. In this study, we aimed to investigate the relationship between TWIST transcription factor expression and the effectiveness of doxorubicin treatment on directly taken primary tumor samples from chemotherapy-naive breast cancer patients. Twenty-six primary breast tumor samples taken from 26 different breast cancer patients were included in this study. Adenosine triphosphate tumor chemo-sensitivity assay (ATP-TCA) has been used to determine tumor response to doxorubicin and real-time reverse-transcription polymerase chain reaction (RT-PCR) was used for analyzing the gene expression of tumors. There was a significant difference in gene expression between responder and non responder tumors ( <0.05). The gene expression of the drug-resistant group was higher than the responsive group. This difference was not dependent on the histopathological features of tumors. In conclusion, compatible with earlier studies that have been performed with cell lines, the current study supports the role of higher gene expression as a biomarker for predicting the response of breast tumors to chemo-therapeutic agent doxorubicin.
机译:阿霉素是乳腺癌辅助化疗中最常用的化学治疗剂之一。在专注于寻找生物标志物以预测患者和肿瘤对所用药物反应的研究中,已建议将Twist转录因子作为预测乳腺肿瘤化学耐药性的候选生物标志物。在这项研究中,我们旨在调查TWIST转录因子表达与阿霉素治疗对未经化疗的乳腺癌患者直接采集的原发肿瘤样品的有效性之间的关系。本研究包括从26位不同的乳腺癌患者中采集的26例原发性乳腺肿瘤样本。三磷酸腺苷肿瘤化学敏感性测定(ATP-TCA)已用于确定肿瘤对阿霉素的反应,实时逆转录聚合酶链反应(RT-PCR)用于分析肿瘤的基因表达。有反应者和无反应者肿瘤之间的基因表达存在显着差异(<0.05)。耐药组的基因表达高于反应组。这种差异不取决于肿瘤的组织病理学特征。总之,与先前对细胞系进行的研究兼容,本研究支持更高基因的表达作为预测乳腺癌对化学治疗剂阿霉素反应的生物标志物的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号